HAROLD O'BRIEN: Open Payments
NPI 1003127358 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,276 in 173 payments from 18 companies in 2025. Trend: 2023 $7,557 · 2024 $2,144 · 2025 $2,276
Food & beverage: $2,276
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $265 |
| Otsuka America Pharmaceutical, Inc. | 26 | $250 |
| Neos Therapeutics, LP | 30 | $250 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $188 |
| Alkermes, Inc. | 14 | $186 |
| Corium, LLC | 16 | $180 |
| Vanda Pharmaceuticals Inc. | 7 | $144 |
| Noven Therapeutics, LLC | 6 | $118 |
| Axsome Therapeutics, Inc. | 4 | $82 |
Products named: VRAYLAR, REXULTI, TRINTELLIX, Adzenys XR-ODT, CAPLYTA, Azstarys, ARISTADA, Xelstrym.
Industry payments across KY — which companies pay providers there.
